Selective estrogen receptor modulators and breast câncer risk reduction: tamoxifen and raloxifene
Keywords:
Raloxifene, Breast câncer, SERMAbstract
Serms (selective estrogen receptor modulators) are agents that blnd to estrogen receptors
and act as estrogen agonlsts In some tissues (bone), and as estrogen antagonists In other
tissues (uterus and breast). Because they act as estrogen-receptors In breast, SERMs have
shown to be effectlve in reducing the risk of breast câncer. The use of tamoxifen in breast
câncer prevention was evaluated in four major clinicai trials and it has been demonstrated that
tamoxifen, used for 5 years, significantly decreases the incidence of breast câncer in high-risk women. The increase in the incidence ofendometrial câncer makes it important to select correctly
the patients who will benefit from tamoxifen therapy. Raloxifene is a second-generation SERM
that binds to estrogen receptors with high affinity. It has estrogen antagonistic activity on the
breast and uterus, and estrogen-like activity on bone. In the More study, the main clinicai trial
done using raloxifeno, a significant reduction in the relative risk of breast câncer of 76% was
demonstrated, in postmenopausal women with osteoporosis, after three years of follow-up.
These results were confirmed after four years of follow-up. The breast câncer risk reduction with raloxifene supports a new perspective in reducing the risk of breast câncer and optimize women's health.
Downloads
References
1.ABE O, ABE R, ENOMOTO K et al.
Tamoxifen for early breast câncer:
an overview of the randomised
trials. Early Breast Câncer Trialists'
Collaborative Group. Lancet 1998; 351:
1451-67.
2.BEATSON 6T. On the treatment of
inoperable cases of the carcinoma of
the mamma: suggestions for a new method of treatment with illustrative
cases. Lancet 1896; ii: 104-7.
3.BENTREM DJ, CRAIG J. Tamoxifen,
raloxifene and the prevention of breast
câncer. Minerva Endocrinol 2002; 27:
127-39.
4.BOYD NF, DITE GS, STONE J et al. Heritability of mammographic density,
a risk factor for breast câncer. N Engl J Med 2002; 347: 886-94.
5.CAULEY J, LUCAS FL, KULLER LH et
al. Elevated serum estradiol and
testosterone concentrations are
associated with a high risk for breast
câncer. Ann Intern Med 1999; 130:
270-7.
6.CAULEY J, NORTON L, LIPPMAN M et al. Continued breast câncer risk reduction
in postmenopausal women treated
with raloxifene: four-year results from
the More trial. Breast Câncer Res Treat
2001; 65: 125-34.
7.CUMMINGS SR, ECKERT S, KRUEGER KA. The effect of raloxifene on risk of breast
câncer in postmenopausal women:
results from the More randomized trial.
JAMA 1999; 281: 2189-97.
8.DALTON RR, KALLAB AM. Chemoprevention
of breast câncer. South Med J 2001; 94:
7-15.
9.DELMAS PD, ENSRUD KE, ADACHIJD et
al. Efficacy of raloxifene on vertebral
fracture risk reduction in postmenopausal women with osteoporosis: four-year
results from a randomized clinicai trial.
J Clin Endocrinol Metab 2002; 87:
3609-17.
10.DELMAS PD, GENANT HK, CRANS GG
et al. Severity of prevalent vertebral
fractures and the risk of subsequent
vertebral and nonvertebral fractures:
results from the More trial. Bone 2003;
33: 522-32.
11.DUNN BK, FORD L. From adjuvant
therapy to breast câncer prevention: BCPT and Star. Breast J 2001; 7:
144-57.
12.FISHER B, CONSTANTINOJP, WICKERHAM
DL et al. Tamoxifen for prevention of
breast câncer: report of the National
Surgical Adjuvant Breast and Bowel
Project: P-l study. J Natl Câncer Inst
1998; 90: 1371-88.
13.GOTTARDIS MM, JORDAN C. Antitumor
actions of keoxifeno and tamoxifen in
the N-nitrosimethylurea-induced rat mammary câncer model. Câncer Res
1987; 48: 4020-4.
14.JACKSON VP, SAN MARTIN J, SECREST RJ et al. Comparison of the effect of
raloxifene and continuous-combined
hormone therapy on mammographic
breast density and breast tenderness
in postmenopausal women. Am J Obstet Gynecol 2003; 188: 389-94.
15.JOLLY EE, BJARNASON NH, NEVEN P. Prevention of osteoporosis and uterine
effects in postmenopausal women taking
raloxifene for five years. Menopause
2003; 10: 337-44.
16.LACASSAGNE A. Hormonal pathogenesis
of adenocarcinoma of the breast. Am J Câncer 1935; 27: 217-25.
17.LIPPMAN ME, BOLAN G. Oestrogenresponsive human breast câncer in
long-term tissue culture. Nature 1975;
256: 592-3.
18.MARICIC M, ADACHI JD, SARKAR S, WU W, WONG M, HARPER KD. Early
effects of raloxifene on clinicai
vertebral fractures at twelve months
in postmenopausal women with
osteoporosis. Arch Intern Med 2002;
162: 1140-3.19.OSBORNE CK. Stèroid hormone
receptors in breast câncer management.
Breast Câncer Res Treat 1998; 51:
227-38.
20.PARK W-C, JORDAN C. Selective estrogen
receptor modulators (Serms) and their
roles in breast câncer prevention. Trends Mol Med 2002; 8: 82-8.
21.PRITCHARD K. Breast câncer prevention with selective estrogen receptor
modulators: a perspective. Ann N Y
Acad Sei 2001; 949: 89-98.
22.SMITH RE, GOOD BC. Chemoprevention
of breast câncer and the trials of the
National Surgical Adjuvant Breast and
Bowel Project and others. Endocr Relat
Câncer 2003; 10: 347-57.
23.STRASSER-WEIPPL K, GOSS PE.
Prevention of breast câncer using Serms
and aromatase inhibitors. Journal of Mammary Gland Biology and Neoplasia
2003; 8: 5-18.
24.VERONESI U, MAISONNEUVE P, COSTA
A et al. Prevention of breast câncer
with tamoxifen: preliminary findings
from the italian randomised trial among
hysterectomised women. Lancet 1998;
352: 93-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Juliana Oliveira, Oswaldo Luís Bracco, Márcia Jehá Kayath, Ezio Novais, Almir Urbanetz, Maurício Magalhães Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
